Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725728 | 0.91 | EPHX1 (0.39) | EPHX1BCHEOPRK1OPRD1FAAH | |
| SCHEMBL1710407 | 0.90 | EPHX1 (0.38) | EPHX1BCHEOPRK1OPRD1MALT1 | |
| SCHEMBL1710885 | 0.85 | BCHE (0.37) | BCHECTSKCTSL | |
| SCHEMBL3386798 | 0.85 | EPHX1 (0.39) | EPHX1OPRK1OPRD1FAAHPTGS2 | |
| SCHEMBL13400277 | 0.83 | EPHX1 (0.38) | EPHX1OPRK1OPRD1FAAHPTGS2 | |
| SCHEMBL1710703 | 0.82 | OPRK1 (0.37) | EPHX1OPRK1OPRD1CTSKCTSS | |
| SCHEMBL1710605 | 0.81 | CA1 (0.38) | EPHX1BCHEOPRK1OPRD1FAAH | |
| SCHEMBL1724792 | 0.80 | IL1B (0.36) | MALT1NQO2 | |
| SCHEMBL13400276 | 0.79 | EPHX1 (0.41) | EPHX1MALT1CTSKNQO2CYP3A4 | |
| SCHEMBL1710644 | 0.79 | CA12 (0.44) | EPHX1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | EPHX1 3213/4885BCHE 2468/4885OPRK1 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.